HENGRUI PHARMA (01276.HK): SHR-3201 wins trial approval for AD
- SHR-3201 injection is a self-developed treatment for Alzheimer's disease that can clear disease biomarkers in patients' brains and slow cognitive decline.
- The product is an injection with acceptance number CXSL2600746, and the application is for the indication of Alzheimer's disease.
NewTimeSpace News: On 13 October 2026, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (stock code: 01276.HK) published an overseas regulatory announcement filed on the Shanghai Stock Exchange website regarding a drug clinical trial approval notice.
Beijing Shengdi Pharmaceutical Co., Ltd., a subsidiary of the Company, received the Drug Clinical Trial Approval Notice issued by China's National Medical Products Administration for SHR-3201 injection, with trials to commence shortly. The product is an injection with acceptance number CXSL2600746; the application accepted on 20 July 2026 meets registration requirements and is approved for the indication of Alzheimer's disease. SHR-3201 injection is a self-developed treatment for Alzheimer's disease that can clear disease biomarkers in patients' brains and slow cognitive decline. No comparable drug is approved in China or overseas, and cumulative R&D investment in the project is about RMB 48.8 million (unaudited).
- HENGRUI PHARMA (01276.HK): Two Drugs Win Clinical Trial Approval in China
- HENGRUI PHARMA (01276.HK): SHR-4595 Gets Clinical Trial Approval in China
- HENGRUI PHARMA (01276.HK): Makes A-Share Repurchase of 335,000 Shares for RMB 14,503,550
- HENGRUI PHARMA (01276.HK): HRS-4139 Tablets Cleared for Clinical Trial in Moderate-to-Severe Plaque Psoriasis
- HENGRUI PHARMA (01276.HK): Recaticimab Cleared for Clinical Trials, Phase III Study Planned in Stroke Recurrence
